Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation.

Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.

Inclusion Criteria:

• Men or women over 15 years of age
• Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant
• Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent.
• Be affiliated with a Health Insurance plan.

Exclusion Criteria:

• Pregnant, parturient and/or lactating woman
• Hemoglobin level less than or equal to 8g/dl
• Persons of full age who are subject to a legal protection measure or who are unable to express their consent
• Persons under the protection of justice
• Not being able to follow the study requirements for geographical, social or psychological reasons
• Patient refusal.